SE460947B - En multiple-unit-dos komposition av l-dopa - Google Patents

En multiple-unit-dos komposition av l-dopa

Info

Publication number: SE460947B
Authority: SE; Sweden
Prior art keywords: dopa; release; composition; hrs; granulate
Prior art date: 1986-08-26

Application number

SE8603582A

Other languages

English (en)

Swedish (sv)

Other versions

SE8603582L (sv

SE8603582D0 (sv

Inventor

C H Appelgren

E C Eskilsson

Original Assignee

Lejus Medical Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-08-26

Filing date

1986-08-26

Publication date

1989-12-11

1986-08-26 Application filed by Lejus Medical Ab filed Critical Lejus Medical Ab

1986-08-26 Priority to SE8603582A priority Critical patent/SE460947B/sv

1986-08-26 Publication of SE8603582D0 publication Critical patent/SE8603582D0/xx

1987-08-21 Priority to ES198787850251T priority patent/ES2036221T3/es

1987-08-21 Priority to AT87850251T priority patent/ATE58292T1/de

1987-08-21 Priority to DE8787850251T priority patent/DE3766200D1/de

1987-08-21 Priority to EP87850251A priority patent/EP0260236B1/fr

1987-08-25 Priority to DK442287A priority patent/DK442287A/da

1987-08-25 Priority to MX007910A priority patent/MX172918B/es

1987-08-25 Priority to CA000545254A priority patent/CA1298198C/fr

1987-08-25 Priority to DD87306327A priority patent/DD286107A5/de

1987-08-25 Priority to NO873589A priority patent/NO176549C/no

1987-08-25 Priority to HU873749A priority patent/HU197211B/hu

1987-08-25 Priority to FI873672A priority patent/FI86689C/fi

1987-08-26 Priority to JP62210363A priority patent/JPH0662405B2/ja

1987-08-26 Priority to PT85591A priority patent/PT85591B/pt

1988-02-27 Publication of SE8603582L publication Critical patent/SE8603582L/xx

1989-07-12 Priority to US07/378,423 priority patent/US4981695A/en

1989-12-11 Publication of SE460947B publication Critical patent/SE460947B/sv

Links

WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title claims abstract description 20
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title claims abstract description 20
239000000203 mixture Substances 0.000 title claims abstract description 15
210000004051 gastric juice Anatomy 0.000 claims abstract description 7
239000008363 phosphate buffer Substances 0.000 claims abstract description 7
239000001856 Ethyl cellulose Substances 0.000 claims description 5
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 5
229920001249 ethyl cellulose Polymers 0.000 claims description 5
235000019325 ethyl cellulose Nutrition 0.000 claims description 5
102000004190 Enzymes Human genes 0.000 claims description 4
108090000790 Enzymes Proteins 0.000 claims description 4
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 4
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 4
239000013543 active substance Substances 0.000 claims description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
150000001875 compounds Chemical class 0.000 abstract 1
239000008187 granular material Substances 0.000 description 22
239000002775 capsule Substances 0.000 description 15
238000002360 preparation method Methods 0.000 description 8
238000009472 formulation Methods 0.000 description 7
230000036470 plasma concentration Effects 0.000 description 5
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000000052 comparative effect Effects 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
-1 hydroxypropyl Chemical group 0.000 description 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
239000003954 decarboxylase inhibitor Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
229940123736 Decarboxylase inhibitor Drugs 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Detergent Compositions (AREA)
Fats And Perfumes (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

SE8603582A 1986-08-26 1986-08-26 En multiple-unit-dos komposition av l-dopa SE460947B (sv)

Priority Applications (15)

Application Number	Priority Date	Filing Date	Title
SE8603582A SE460947B (sv)	1986-08-26	1986-08-26	En multiple-unit-dos komposition av l-dopa
ES198787850251T ES2036221T3 (es)	1986-08-26	1987-08-21	Procedimiento para preparar una composicion de l-dopa de dosis unitaria multiple.
AT87850251T ATE58292T1 (de)	1986-08-26	1987-08-21	L-dopa enthaltendes arzneimittel.
DE8787850251T DE3766200D1 (de)	1986-08-26	1987-08-21	L-dopa enthaltendes arzneimittel.
EP87850251A EP0260236B1 (fr)	1986-08-26	1987-08-21	Composition contenant de la L-dopa
FI873672A FI86689C (fi)	1986-08-26	1987-08-25	Foerfarande foer framstaellning av en multipel-unit-doskomposition, som innehaoller l-dopa som farmaceutiskt aktiv substans
MX007910A MX172918B (es)	1986-08-26	1987-08-25	Composicion a base de l-3,4-dihidroxifenilalanina
DK442287A DK442287A (da)	1986-08-26	1987-08-25	Farmaceutisk praeparat indeholdende l-3,4-dihydroxyphenylalanin (l-dopa) som aktiv bestanddel og fremgangsmaade til fremstilling af et saadant praeparat
CA000545254A CA1298198C (fr)	1986-08-26	1987-08-25	Composition comportant de la l-dopa
DD87306327A DD286107A5 (de)	1986-08-26	1987-08-25	Zusammensetzung mit mehrfachdosierung, die als pharmazeutisch wirksame verbindung entfaellt
NO873589A NO176549C (no)	1986-08-26	1987-08-25	Fremgangsmåte for fremstilling av L-dopa-kjerner med 2 overtrekk
HU873749A HU197211B (en)	1986-08-26	1987-08-25	Process for producing pharmaceutical composition containing l-dopa as active component coated with coating for regulating release of the active components
JP62210363A JPH0662405B2 (ja)	1986-08-26	1987-08-26	Ｌ―ドーパ含有組成物
PT85591A PT85591B (pt)	1986-08-26	1987-08-26	Processo para a preparacao de composicoes farmaceuticas sob a forma de dose unitaria-multipla contendo l-dopa
US07/378,423 US4981695A (en)	1986-08-26	1989-07-12	Composition comprising L-dopa

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE8603582A SE460947B (sv)	1986-08-26	1986-08-26	En multiple-unit-dos komposition av l-dopa

Publications (3)

Publication Number	Publication Date
SE8603582D0 SE8603582D0 (sv)	1986-08-26
SE8603582L SE8603582L (sv)	1988-02-27
SE460947B true SE460947B (sv)	1989-12-11

Family

ID=20365397

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE8603582A SE460947B (sv)	1986-08-26	1986-08-26	En multiple-unit-dos komposition av l-dopa

Country Status (15)

Country	Link
US (1)	US4981695A (fr)
EP (1)	EP0260236B1 (fr)
JP (1)	JPH0662405B2 (fr)
AT (1)	ATE58292T1 (fr)
CA (1)	CA1298198C (fr)
DD (1)	DD286107A5 (fr)
DE (1)	DE3766200D1 (fr)
DK (1)	DK442287A (fr)
ES (1)	ES2036221T3 (fr)
FI (1)	FI86689C (fr)
HU (1)	HU197211B (fr)
MX (1)	MX172918B (fr)
NO (1)	NO176549C (fr)
PT (1)	PT85591B (fr)
SE (1)	SE460947B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4983400A (en) *	1986-06-16	1991-01-08	Merck & Co., Inc.	Controlled release combination of carbidopa/levodopa
US4832957A (en) *	1987-12-11	1989-05-23	Merck & Co., Inc.	Controlled release combination of carbidopa/levodopa
CA2007181C (fr) *	1989-01-06	1998-11-24	Angelo Mario Morella	Compose pharmaceutique a liberation continue
US5202128A (en) *	1989-01-06	1993-04-13	F. H. Faulding & Co. Limited	Sustained release pharmaceutical composition
CA2007055A1 (fr) *	1989-01-06	1990-07-06	Garth Boehm	Forme posologique de theophylline
US5196203A (en) *	1989-01-06	1993-03-23	F. H. Faulding & Co. Limited	Theophylline dosage form
DE4101873C2 (de)	1991-01-23	1993-12-09	Isis Pharma Gmbh	Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5478572A (en) *	1994-09-06	1995-12-26	Bristol-Myers Squibb Co.	Gepirone dosage form
US6992107B1 (en)	1995-03-10	2006-01-31	Photocure Asa	Esters of 5-aminolevulinic acid and their use as photosensitizing compounds in photochemotherapy
US6492420B2 (en)	1995-03-10	2002-12-10	Photocure As	Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
US7530461B2 (en)	1995-03-10	2009-05-12	Photocure Asa	Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
US5997831A (en) *	1996-07-12	1999-12-07	Engelhard Corporation	Method of catalytically treating the atmosphere and heat exchange devices produced thereby
UA73981C2 (en) *	2000-03-10	2005-10-17	Merck Patent Gmbh	(r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
GB0018528D0 (en)	2000-07-27	2000-09-13	Photocure Asa	Compounds
PT1408964E (pt) *	2001-07-26	2007-05-31	Merck Patent Gmbh	Utilização de 2-5-(4-fluorofenil) -3-piridilmetilaminometil-cromano e de seus sais fisiologicamente aceitáveis.
EP1490073A4 (fr) *	2002-03-21	2006-02-01	Martin C Hinz	Technologie d'optimisation d'un segment de systeme de serotonine et catecholamine
ITMI20030827A1 (it) *	2003-04-18	2004-10-19	Unihart Corp	Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
KR20060108692A (ko) *	2003-10-31	2006-10-18	알자 코포레이션	메트포르민의 개선된 흡수를 위한 조성물 및 제형
CA2549195A1 (fr) *	2003-12-09	2005-06-23	Spherics, Inc.	Polymeres bioadhesifs a fonction catechol
US20080311191A1 (en) *	2004-08-27	2008-12-18	Avinash Nangia	Multi-Layer Tablets and Bioadhesive Dosage Forms
CA2613631A1 (fr) *	2005-06-23	2007-01-04	Spherics, Inc.	Formes de dosage ameliorees pour le traitement de troubles moteurs
AR055106A1 (es) *	2005-08-05	2007-08-08	Osmotica Pharmaceutical Argent	Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa
EP1988887A2 (fr) *	2006-01-13	2008-11-12	University of South Carolina	Méthode et composition pour le traitement de la maladie de parkinson
EP2086515A2 (fr) *	2006-03-02	2009-08-12	Vaunnex, Inc.	Formulations bioadhésives posologiques orales a liberation controlee
US20080131492A1 (en) *	2006-06-23	2008-06-05	Spherics, Inc.	Dosage forms for movement disorder treatment
AU2007338631A1 (en) *	2006-12-22	2008-07-03	Combinatorx, Incorporated	Pharmaceutical compositions for treatment of parkinson's disease and related disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1116256A (fr) *	1954-12-09	1956-05-07		Stylographe à bille
DE1128461B (de) *	1959-01-15	1962-04-26	Fernseh Gmbh	Einrichtung zum Schutz einer Fernsehaufnahmeroehre gegen Fehl-bedienung ihrer motorisch angetriebenen Lichtstromregeleinrichtung
FR2116256A1 (en) *	1970-12-02	1972-07-13	Sobio Lab	Enteric - coated l-dopa - for treatment of parkinsonism with reduced gastrointestinal side-effects
JPS5518694B2 (fr) *	1973-04-02	1980-05-21
DE2343218C2 (de) *	1973-08-28	1986-08-07	Hoechst Ag, 6230 Frankfurt	Furosemid enthaltende Pellets
DE2513940A1 (de) *	1975-03-29	1976-10-14	Merck Patent Gmbh	Pharmazeutische zubereitung
DE2655331A1 (de) *	1976-12-07	1978-06-08	Hoechst Ag	Zubereitungsformen von 3-n-pyrrolidino-4-phenoxy-5-sulfamyl-benzoesaeure und verfahren zu ihrer herstellung
JPS5436645A (en) *	1977-08-29	1979-03-17	Omron Tateisi Electronics Co	Temperature control system for boiler
CH627077A5 (en) *	1978-01-01	1981-12-31	Sankyo Co	Pharmaceutical composition which foams in the intestine
CH649216A5 (de) *	1979-08-16	1985-05-15	Sandoz Ag	Verfahren zur auftragung eines magensaftresistenten filmes auf einen heilmittelkern und feste einheitsdosierungsform mit magensaftresistentem film.
DE3000979A1 (de) *	1980-01-12	1981-07-23	Dr. Karl Thomae Gmbh, 7950 Biberach	Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
CH652025A5 (de) *	1981-09-14	1985-10-31	Hoffmann La Roche	Pharmazeutisches praeparat.
DK150008C (da) *	1981-11-20	1987-05-25	Benzon As Alfred	Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4446138A (en) *	1982-02-10	1984-05-01	Pack Howard M	Method and composition for reducing weight
JPS59139317A (ja) *	1983-01-31	1984-08-10	Teisan Seiyaku Kk	持続性のニフエジピン製剤
IE56459B1 (en) *	1983-12-21	1991-08-14	Elan Corp Ltd	Controlled absorption pharmaceutical formulation
NZ220599A (en) *	1986-06-16	1990-10-26	Merck & Co Inc	Controlled release oral dosage formulation of carbidopa and levodopa

1986
- 1986-08-26 SE SE8603582A patent/SE460947B/sv not_active IP Right Cessation
1987
- 1987-08-21 ES ES198787850251T patent/ES2036221T3/es not_active Expired - Lifetime
- 1987-08-21 AT AT87850251T patent/ATE58292T1/de not_active IP Right Cessation
- 1987-08-21 DE DE8787850251T patent/DE3766200D1/de not_active Expired - Lifetime
- 1987-08-21 EP EP87850251A patent/EP0260236B1/fr not_active Expired - Lifetime
- 1987-08-25 HU HU873749A patent/HU197211B/hu unknown
- 1987-08-25 MX MX007910A patent/MX172918B/es unknown
- 1987-08-25 NO NO873589A patent/NO176549C/no unknown
- 1987-08-25 DD DD87306327A patent/DD286107A5/de not_active IP Right Cessation
- 1987-08-25 CA CA000545254A patent/CA1298198C/fr not_active Expired - Lifetime
- 1987-08-25 DK DK442287A patent/DK442287A/da not_active Application Discontinuation
- 1987-08-25 FI FI873672A patent/FI86689C/fi not_active IP Right Cessation
- 1987-08-26 JP JP62210363A patent/JPH0662405B2/ja not_active Expired - Lifetime
- 1987-08-26 PT PT85591A patent/PT85591B/pt not_active IP Right Cessation
1989
- 1989-07-12 US US07/378,423 patent/US4981695A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
PT85591A (en)	1987-09-01
DK442287A (da)	1988-02-27
NO873589L (no)	1988-02-29
ATE58292T1 (de)	1990-11-15
DE3766200D1 (de)	1990-12-20
HU197211B (en)	1989-03-28
EP0260236B1 (fr)	1990-11-14
FI873672L (fi)	1988-02-27
MX172918B (es)	1994-01-21
FI873672A0 (fi)	1987-08-25
EP0260236A1 (fr)	1988-03-16
ES2036221T3 (es)	1993-05-16
NO176549B (no)	1995-01-16
PT85591B (pt)	1990-05-31
SE8603582L (sv)	1988-02-27
FI86689B (fi)	1992-06-30
NO176549C (no)	1995-04-26
NO873589D0 (no)	1987-08-25
DD286107A5 (de)	1991-01-17
HUT44438A (en)	1988-03-28
US4981695A (en)	1991-01-01
FI86689C (fi)	1992-10-12
CA1298198C (fr)	1992-03-31
JPH0662405B2 (ja)	1994-08-17
JPS63139128A (ja)	1988-06-10
SE8603582D0 (sv)	1986-08-26
DK442287D0 (da)	1987-08-25

Legal Events

Date

Code

Title

Description

1995-01-31

NUG

Patent has lapsed

Ref document number: 8603582-1

Effective date: 19920306

Format of ref document f/p: F

Publication	Publication Date	Title
SE460947B (sv)	1989-12-11	En multiple-unit-dos komposition av l-dopa
US4794001A (en)	1988-12-27	Formulations providing three distinct releases
ES2226886T3 (es)	2005-04-01	Forma de administracion de accion retardada que contiene sacarinato de tramadol.
FI84556B (fi)	1991-09-13	Foerfarande foer framstaellning av en formulation av kefaklor med laong verkan.
US4367217A (en)	1983-01-04	Dipyricamole sustained release forms comprising lacquer-coated particles and the preparation thereof
CA1264296A (fr)	1990-01-09	Formules a trois niveaux distincts de liberation
US4309404A (en)	1982-01-05	Sustained release pharmaceutical compositions
US20040234601A1 (en)	2004-11-25	Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
EP0711152B1 (fr)	2002-12-04	Formes galeniques pour une administration orale, ayant une couche de poudre
US4462991A (en)	1984-07-31	Method of increasing oral absorption of polar bioactive agents
CA1323576C (fr)	1993-10-26	Preparation de diclofenac sodium, a action prolongee
US7611730B2 (en)	2009-11-03	Tramadol-based medicament
US20110189269A1 (en)	2011-08-04	Extended release composition containing tramadol
EP0660705A1 (fr)	1995-07-05	Systeme et methode perfectionnes d'administration de medicaments et de traitement des affections psychiatriques, neurologiques et autres avec la carbamazepine
CA2653403A1 (fr)	2007-12-06	Granules d'acide lipoique
KR20190080875A (ko)	2019-07-08	모발 성장 자극을 위한 알파-케토부티레이트, 알파-케토글루타레이트, 및 2-하이드록시부티레이트
US20030215506A1 (en)	2003-11-20	Methods and compositions for enhancement of creatine transport
HK1045107A1 (en)	2002-11-15	Morphine sulphate microgranules, method for preparing same and compositions containing same
US4968506A (en)	1990-11-06	Pharmaceutical dosage with core of N-acetyl cystein
SI21301A (sl)	2004-04-30	Farmacevtska oblika z nadzorovanim sproščanjem
EP0287536A1 (fr)	1988-10-19	Composition pharmaceutique de quinidine
US5968552A (en)	1999-10-19	Diltiazem hydrochloride formulation
EP0447168A2 (fr)	1991-09-18	Composition pharmaceutique granulaire à effet prolongé
WO1997020562A1 (fr)	1997-06-12	Liberation retard de cisapride
JP2009514784A (ja)	2009-04-09	経口リバビリン医薬組成物